CD8A and type 1 diabetes mellitus: Furthermore, it has been observed that patients with T1D who responded effectively to teplizumab (CD3) treatment had a higher percentage of partially exhausted CD8+ EOMES+ KLRG1+ TIGIT+ T cells [46].